Core Viewpoint - Yahui Pharmaceutical (688176) has seen a stock price increase of 4.31% this week, closing at 10.16 RMB as of November 14, 2025, with a total market capitalization of 5.803 billion RMB [1] Company Announcements - Yahui Pharmaceutical has completed a change in registered capital, with the new registered capital amounting to 571.170486 million RMB [1] - The company held a board and supervisory board meeting on August 28, 2025, and an extraordinary shareholders' meeting on September 23, 2025, where it approved the cancellation of the supervisory board, change in registered capital, and amendments to the company’s articles of association [1] - The company has received a new business license from the Taizhou Market Supervision Administration reflecting the changes in registered capital [1]

证券代码：688176 证券简称：亚虹医药 公告编号：2025-042 江苏亚虹医药科技股份有限公司 关于完成注册资本变更并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日 召开第二届董事会第十八次会议、第二届监事会第十四次会议，于 2025 年 9 月 23 日召开 2025 年第二次临时股东大会，审议通过了《关于取消监事会、变更注 册资本、修订<公司章程>并办理工商变更登记的议案》，同意公司取消监事会、 注册资本变更、修订《江苏亚虹医药科技股份有限公司章程》并办理工商变更登 记。具体内容详见公司分别于 2025 年 8 月 29 日、2025 年 9 月 24 日披露于上海 证券交易所网站（www.sse.com.cn）的《江苏亚虹医药科技股份有限公司关于取 消监事会、变更注册资本、修订<公司章程>并办理工商变更登记及修订、制定 公司部分治理制度的公告》（公告编号：2025-034）、《江苏亚虹医药科技股份有 限公司 ...

Core Insights - A new investment fund named Changzhou Liyang Qifan New Industry Investment Fund Partnership (Limited Partnership) has been established with a capital contribution of 1 billion yuan [1] - The fund's business scope includes private equity investment, investment management, and asset management activities [1] - The fund is co-held by companies such as Yahu Pharmaceutical and Silergy Semiconductor Technology (Hangzhou) Co., Ltd [1]

Core Points - The stock price of Yahui Pharmaceutical (688176.SH) closed at 9.81 yuan, reflecting a decline of 1.6% and indicating a state of breaking issue [1] - Yahui Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an issuance of 110 million shares at a price of 22.98 yuan per share [1] - The stock experienced a break on its first trading day, with an intraday high of 20.00 yuan, which remains the highest price since its listing [1] Fundraising and Financials - The total amount raised from the initial public offering (IPO) was 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs [1] - The net amount raised exceeded the original plan by 311 million yuan, with the company initially aiming to raise 2.070 billion yuan [1] - The total issuance costs for the IPO amounted to 147 million yuan, with CITIC Securities receiving 130 million yuan as underwriting and sponsorship fees [1] Project Allocation - The funds raised are intended for various projects, including drug and medical device production, new drug research and development, marketing network construction, and supplementing working capital [1] Company Leadership - The controlling shareholder, actual controller, chairman, and general manager of Yahui Pharmaceutical is PAN KE, who holds American nationality [1]

Core Viewpoint - Yahui Pharmaceutical, established in March 2010 and listed on the Shanghai Stock Exchange in January 2022, focuses on innovative drug development for urogenital tumors and other diseases, showcasing strong technical capabilities in R&D [1] Financial Performance - For Q3 2025, Yahui Pharmaceutical reported revenue of 216 million yuan, ranking 97th out of 110 in the industry, significantly lower than the top competitors, East China Pharmaceutical (32.664 billion yuan) and Fosun Pharmaceutical (29.393 billion yuan), and below the industry average of 280 million yuan and median of 83.8 million yuan [2] - The company incurred a net loss of 261 million yuan, ranking 106th out of 110, with a stark contrast to the leading companies, Heng Rui Medicine (5.76 billion yuan) and Fosun Pharmaceutical (3.056 billion yuan), and below the industry average of 299 million yuan and median of 78.29 million yuan [2] Financial Ratios - As of Q3 2025, Yahui Pharmaceutical's debt-to-asset ratio was 19.20%, an increase from 10.12% year-on-year, but still below the industry average of 35.26%, indicating relatively low debt pressure [3] - The gross profit margin for the same period was 74.76%, down from 79.44% year-on-year, yet higher than the industry average of 57.17%, suggesting a competitive edge in profitability [3] Executive Compensation - The chairman and general manager, Pan Ke, received a salary of 3.5808 million yuan in 2024, an increase of 168,400 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.06% to 25,200, while the average number of circulating A-shares held per shareholder increased by 16.41% to 17,300 [5] - The top ten circulating shareholders included Penghua Pharmaceutical Technology Stock A, which held 6.1424 million shares, a decrease of 401,700 shares from the previous period [5] Growth Prospects - According to Pacific Securities, Yahui Pharmaceutical's revenue grew by 62% year-on-year in the first half of 2025, primarily driven by the commercial success of its products, Pazopanib tablets and Naltrindole tablets [5] - The company has a strong cash reserve of approximately 1.825 billion yuan as of the end of Q2 2025, and its core product APL-1702 is progressing well towards approval, expected by the end of 2025 or early 2026 [5] - Southwest Securities noted that the company is focusing on deepening its product pipeline with self-developed small molecules and ADC innovative drugs, projecting revenues of 300 million, 500 million, and 740 million yuan for 2025, 2026, and 2027 respectively [6]

Core Viewpoint - The company, Jiangsu Yahon Pharmaceutical Technology Co., Ltd., has released its quarterly report, ensuring the accuracy and completeness of the financial information presented, and confirming that there are no false records or misleading statements [2][3]. Financial Data Summary - The financial statements for the third quarter are unaudited, covering the period from the beginning to the end of the quarter [3][8]. - The report includes major accounting data and financial indicators, with all figures presented in Renminbi [3][8]. - The company has a share repurchase account holding 8,667,675 shares, representing 1.52% of total shares [5]. Non-Recurring Gains and Losses - The report indicates that non-recurring gains and losses are applicable, but specific details on significant items are not provided [4]. Shareholder Information - The report does not include information on major shareholders or changes in shareholding due to securities lending [6][7].

Core Viewpoint - Yahuang Pharmaceutical announced the election of Mr. Chen Baohua as the employee director of the company's second board of directors during the employee representative meeting scheduled for October 29, 2025 [1] Summary by Categories - **Company Announcement** - Yahuang Pharmaceutical will hold an employee representative meeting on October 29, 2025 [1] - Mr. Chen Baohua has been elected as the employee director of the second board of directors [1]

Core Insights - The company achieved a total operating revenue of 216 million yuan in the first three quarters of 2025, representing a year-on-year increase of 55.74% [1] - The net profit attributable to shareholders of the parent company was -249 million yuan, which is a reduction in losses by 21.89 million yuan compared to the same period last year [1] - The basic earnings per share stood at -0.44 yuan [1]

中信证券股份有限公司 关于江苏亚虹医药科技股份有限公司 使用自有资金支付募投项目所需资金并以募集资金等额置换的 核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏亚 虹医药科技股份有限公司（以下简称"公司"或"上市公司"）首次公开发行股 票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》、《上海 证券交易所科创板股票上市规则》等相关规定，对公司使用自有资金支付募投项 目所需资金并以募集资金等额置换事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意江苏亚虹医药科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕3797 号）同意注册，公司向社 会公开发行人民币普通股 11,000 万股，每股面值人民币 1 元，每股发行价为人 民币 22.98 元，募集资金总额为人民币 252,780.00 万元，实际募集资金净额为人 民币 238,059.22 万元。以上募集资金到位情况已经立信会计师事务所（特殊普通 合伙）审验并出具了《验资报告》（信会计师报字[2021]第 ZA15998 号）。 二、募投项目的基本情况 根据《江苏 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2025-040 江苏亚虹医药科技股份有限公司 关于选举第二届董事会职工董事及聘任高级管理人 员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开职工代表大会并做出决议，选举陈宝华先生为公司第二届董事会职工董事； 于同日召开第二届董事会第十九次会议，审议通过了《关于聘任高级管理人员的 议案》，同意聘任陈宝华先生为公司财务负责人、董事会秘书。现将相关情况公 告如下： 一、 职工董事的选举情况 依据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交易所 科创板股票上市规则》和《江苏亚虹医药科技股份有限公司章程》（以下简称"《公 司章程》"）等法律法规、规范性文件的要求，公司于 2025 年 10 月 29 日召开职 工代表大会并做出决议，选举陈宝华先生（简历详见附件）为公司第二届董事会 职工董事，任期自公司职工代表大会决议之日起至第二届董事会任期届满之日止。 经公司董 ...